Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$15.39MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott Plesha
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 3.11
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.06
Financials
Revenue
$15.39M+107.9%Net Income
$-7.89MEBITDA
$-5.63MFree Cash Flow
$-5.22MEPS (diluted)
$-2.04Shares Outstanding (diluted)
3.86M+557.2%Operating Expenses
$19.86MCash & Debt
$17.69MReturn of Capital
$0.00Revenue by Segment (annual)
$589.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.80M | $-43.32M | $-23.04 |
| 2024 | $0.00 | $-7.96M | $-13.54 |
| 2023 | $0.00 | $-7.38M | $-12.80 |
| 2022 | $0.00 | $-2.46M | $-4.26 |
| 2021 | $0.00 | $-595.4K | $-1.00 |
| 2020 | $199.9K | $-660.6K | $-1.15 |
Valuation
PTHShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-23.81%Social Signal Score
Mentions (6)
- Newszacks.com·10d ago·Negative
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $2.83. This compares to a loss of $5.3 per share a year ago.
View source ↗ - Newsglobenewswire.com·23d ago·Negative
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB)
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
…y coverage for ZELSUVMI increases to 127 million commercially covered lives DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced that it signed an agreement with a major Pharmacy Benefit Manager (“PBM”) to open access to ZELSUVMI® (berdazimer) topical gel, 10.3%, covering 24 million covered lives…
View source ↗ - Newsmarketbeat.com·100d ago·Positive
Pelthos Therapeutics Q2 Earnings Call Highlights Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.
View source ↗ - Newszacks.com·101d ago·Negative
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026
View source ↗
Earnings
Thu, Mar 18(in 4 months)
Consensus estimate $-2.50 per share
Typical surprise -10.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-2.04 vs $-3.08beat
- Thu, Aug 13$-6.62 vs $-2.82miss
- Thu, May 14$-3.09 vs $-3.45beat
- Thu, Mar 19$-6.87 vs $-3.95miss
- Thu, Nov 13$-5.30 vs $-0.67miss
- Wed, Aug 13$-5.38 vs $-5.82beat
Estimates and results for PTHS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PTHS officers and directors.
- Bought
- $1.4m
- Sold
- $486k
3 trades
24 trades
- Greenleaf Petersold
- Friedberg Ezra Msold
- Pauls Matthewsold
- Friedberg Ezra Msold
- Friedberg Ezra Msold
- Pauls Matthewsold
- Pauls Matthewsold
- Greenleaf Petersold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PTHS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
